2023 ASCO Annual Meeting - Focus on Leukemia
The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting took place June 2 through June 6 in Chicago, Illinois. The meeting featured plenary sessions, posters, talks, and more updates on the latest research in hematologic oncology.
This section of news from the 2023 ASCO Annual Meeting focused on the latest developments in leukemia treatment and research from the meeting, including updates from clinical trials, data on novel therapies, and more.
Advertisement
Advertisement
The three-year cumulative incidence of relapse was 4% in those receiving cladribine and low-dose cytarabine plus venetoclax.
Of the 8,081 patients evaluated, 4,808 received treatment within 24 months of a novel therapy approval.
The real-world analysis of racial disparities in CLL accounted for the treatment that patients received.
Dr. Cortes and colleagues presented the research during the 2023 American Society of Clinical Oncology Annual Meeting.
The study included patients who received at least two prior lines of therapy, including a BTK inhibitor.
Older adult patients with newly diagnosed Ph- ALL may benefit from this combination therapy.
In this poor-risk population of patients, 73% responded to the triplet.
Researchers reported real-world patterns and outcomes by race and line of therapy in a poster presentation at ASCO.
However, more than half (53%) of patients discontinued at least one venetoclax regimen.
Dr. Hill and colleagues presented their research on the CAR-T manufacturing approach during the 2023 ASCO meeting.
The study is currently enrolling patients who have previously received a Bruton tyrosine kinase inhibitor.
